MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson's program
Synaffix and MacroGenics have signed a deal to codevelop and commercialize a clinical platform for antibody-drug conjugates to fight cancer.
Synaffix will license out its GlycoConnect antibody conjugation platform, polar spacer technology and toxSYN linker payloads. In return, it will get $586 million in upfront and milestone payments across the three programs and is eligible for royalties on commercial sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.